WO1998007844A3 - Screening assay for the identification of agents which alter expression of pth-rp - Google Patents

Screening assay for the identification of agents which alter expression of pth-rp Download PDF

Info

Publication number
WO1998007844A3
WO1998007844A3 PCT/US1997/014836 US9714836W WO9807844A3 WO 1998007844 A3 WO1998007844 A3 WO 1998007844A3 US 9714836 W US9714836 W US 9714836W WO 9807844 A3 WO9807844 A3 WO 9807844A3
Authority
WO
WIPO (PCT)
Prior art keywords
pth
agents
expression
assayable product
production
Prior art date
Application number
PCT/US1997/014836
Other languages
French (fr)
Other versions
WO1998007844A2 (en
Inventor
Gregory R Mundy
Wolfgang E Gallwitz
Original Assignee
Osteoscreen
Gregory R Mundy
Wolfgang E Gallwitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteoscreen, Gregory R Mundy, Wolfgang E Gallwitz filed Critical Osteoscreen
Priority to AU41587/97A priority Critical patent/AU4158797A/en
Publication of WO1998007844A2 publication Critical patent/WO1998007844A2/en
Publication of WO1998007844A3 publication Critical patent/WO1998007844A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A cell-based assay technique for identifying and evaluating chemical compounds and agents which affect the production of Pth-rP in mammalian cells and other cell types is set forth. Specifically , tumor cell lines are transformed with an expression vector comprising a DNA sequence encoding a promoter region of PTH-rP operatively linked to a reporter gene encoding an assayable product and cultured under conditions which permit expression of the assayable product. Chemical agent and factors can then be identified by their ability to modulate the expression of the reporter gene, thereby affecting the production of the assayable product. Such agents are then tested for inhibitory effects on tumor cell growth and for stimulatory effects on bone formation and repair.
PCT/US1997/014836 1996-08-23 1997-08-22 SCREENING ASSAY FOR THE IDENTIFICATION OF AGENTS WHICH ALTER EXPRESSION OF PTH-rP WO1998007844A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU41587/97A AU4158797A (en) 1996-08-23 1997-08-22 Screening assay for the identification of agents which alter expression of pth-rp

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2521596P 1996-08-23 1996-08-23
US60/025,215 1996-08-23
US08/915,868 US5914233A (en) 1996-08-23 1997-08-21 Screening assay for the identification of agents which alter expression of PTH-rP
US08/915,868 1997-08-21

Publications (2)

Publication Number Publication Date
WO1998007844A2 WO1998007844A2 (en) 1998-02-26
WO1998007844A3 true WO1998007844A3 (en) 1998-08-27

Family

ID=26699451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014836 WO1998007844A2 (en) 1996-08-23 1997-08-22 SCREENING ASSAY FOR THE IDENTIFICATION OF AGENTS WHICH ALTER EXPRESSION OF PTH-rP

Country Status (3)

Country Link
US (2) US5914233A (en)
AU (1) AU4158797A (en)
WO (1) WO1998007844A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005416A2 (en) * 1998-07-23 2000-02-03 Georgetown University Fgf-bp promoter sequences as sensors of drug effects
DE69924027T2 (en) * 1998-09-04 2005-07-21 Aventis Pharmaceuticals Inc. LUCIFERASE REPORTER TEST PROCEDURE FOR PARATHYROIDHORMONE COMPOUNDS
EP1385994A2 (en) * 2001-04-02 2004-02-04 Bayer HealthCare AG Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructs
CA2496761C (en) 2002-08-21 2015-06-02 Revivicor, Inc. Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
EP1393720A1 (en) * 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1601576A4 (en) 2003-03-03 2007-12-05 Univ Columbia Ligand/binding partner bio-labeling systems
WO2006014899A2 (en) 2004-07-26 2006-02-09 Dow Global Technologies Inc. Process for improved protein expression by strain engineering
EP3138403A1 (en) 2005-08-09 2017-03-08 Revivicor, Inc. Transgenic ungulates expressing ctla4-ig and uses thereof
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
AU2008245696B2 (en) 2007-04-27 2013-11-07 Pelican Technology Holdings, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022790A1 (en) * 1995-01-23 1996-08-01 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487298A3 (en) * 1990-11-21 1992-12-16 Schering Corporation Human gamma interferon antagonist/agonist screen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022790A1 (en) * 1995-01-23 1996-08-01 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALAM J ET AL: "REPORTER GENES: APPLICATION TO THE STUDY OF MAMMALIAN GENE TRANSCRIPTION", ANALYTICAL BIOCHEMISTRY, vol. 188, no. 2, 1 August 1990 (1990-08-01), pages 245 - 254, XP000563914 *
BOUIZAR ET AL.: "POLYMERASE CHAIN REACTION ANALYSIS OF PARATHYROID HORMONE-RELATED PROTEIN GENE EXPRESSION IN BREAST CANCER PATIENTS AND OCCURRENCE OF BONE METASTASES", CANCER RESEARCH, vol. 53, 1993, pages 5076 - 5078, XP002051653 *
M.L. CASEY ET AL.: "Regulation of parathyroid hormone-related protein gene expression in human endometrial stromal cells in culture.", J. CLIN. ENDOCRINOL. METAB., vol. 77, no. 1, 1993, pages 188 - 194, XP002068021 *
MANGIN ET AL.: "IDENTIFICATION OF AN UP-STREAM PROMOTER OF THE HUMAN PARATHYROID HORMONE-RELATED PEPTIDE GENE", MOL. ENDOCRINOLOGY, vol. 4, 1990, pages 851 - 858, XP002051652 *
S .BUDAVARI , EDITOR: "the merck index", 1996, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, NJ, USA, XP002068022 *
S BUDAVARI, EDITOR: "the merck index", 1996, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, NJ,USA, XP002068023 *
WYSOLMERSKI ET AL.: "TRANSACTIVATION OF THE PTHRP GENE IN SQUAMOUS CARCINOMAS PREDICTS THE OCCURRENCE OF HYPERCALCEMIA IN ATHYMIC MICE", CANCER RESEARCH, vol. 56, 1996, pages 1043 - 1049, XP002051650 *
YU ET AL.: "VITAMIN D ANALOGS: NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF SQUAMOUS CANCER AND ITS ASSOCIATED HYPERCALCEMIA", ANTI-CANCER DRUGS, vol. 6, 1995, pages 101 - 108, XP002051651 *

Also Published As

Publication number Publication date
US20020061509A1 (en) 2002-05-23
AU4158797A (en) 1998-03-06
US5914233A (en) 1999-06-22
WO1998007844A2 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
WO1998007844A3 (en) Screening assay for the identification of agents which alter expression of pth-rp
Paul et al. Nutrient and energy flows through soil microbial biomass
US9574174B2 (en) Cell culture
Coffino et al. Immunoglobulin production: method for quantitatively detecting variant myeloma cells
ATE397089T1 (en) METHOD FOR SCREENING MULTIPLE TRANSFORMED CELLS USING BICISTRONIC EXPRESSION OF FLUORESCENT PROTEINS
DE69618350T2 (en) A METHOD FOR DETECTING BIOLOGICALLY ACTIVE SUBSTANCES
Bates et al. The synthesis of underhydroxylated collagen by 3T6 mouse fibroblasts in culture
WO1996006168A3 (en) Retinoblastoma protein-interacting zinc finger proteins
CA2250174A1 (en) Test media and quantitative method for identification and differentiation of biological materials in a test sample
DE69723855D1 (en) METHOD FOR PRODUCING POLYPEPTIDES IN SURFACTIN MUTANTS FROM BACILLUS CELLS
Beekhuis-Hoekstra et al. Systematic assessment of variability in the proteome of iPSC derivatives
Howard et al. Use of Coomassie blue-polyurethane interaction inscreening of polyurethanase proteins andpolyurethanolytic bacteria
RU2005122470A (en) METHOD FOR OBTAINING A GENETICALLY MODIFIED ORGANISM FOR SCREENING BIOLOGICALLY ACTIVE SUBSTANCES
CN103320494A (en) Method for measuring invasiveness of multiple cells to cell matrix embedded with endothelial cells by utilizing Transwell
WO1995030009A3 (en) Identification, production and use of saponin glyclosyl hydrolases
Kleijer et al. Prenatal diagnosis of citrullinemia: elevated levels of citrulline in the amniotic fluid in the three affected pregnancies
WO2000058521A3 (en) Methods for the identification of reporter and target molecules using comprehensive gene expression profiles
Versteegh et al. Variations in the amounts of RNA polymerase forms I, II and III during preimplantation development in the mouse
BR9708256A (en) Process for identifying genes with specific expression to the site or preferred site in specific labeling cells present in a cell environment different or not from that of its origin and use
Schachner et al. Queuine deficiency and restoration in Dictyostelium discoideum and related early developmental changes
Murphy et al. Determination of multiple forms of esterases in Rhizobium by paper electrophoresis
Williams et al. The starch-gel electrophoresis of glucose-6-phosphate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase of Streptococcus faecalis, S. faecium and S. durans
De Petrocellis et al. Role of cell interactions in development and differentiation of the sea urchin Paracentrotus lividus: Changes in the activity of some enzymes of DNA biosynthesis after cell dissociation
Patel et al. Factors influencing filament length of Methanospirillum hungatii
Kiessling et al. DNA polymerase activity in preimplantation mouse embryos

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998511015

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA